OUP (Osage University Partners)
OUP is a venture capital fund investing in start-ups that commercialize university research.
Business Model: Education
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed OUP (Osage University Partners) Information
Geographic Data
Address: 50 Monument Road
City: Bala Cynwyd
State: CA
Zip: 19004
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$350M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
4,859,126Website Global Rank
1,766Website Monthly Traffic
Twitter Followers
Description
Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.
Contact Phone:
+14844342255
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2023 | Hack The Box | Series B | 0 |
| 4/2018 | Synthorx | Series C | 63M |
| 3/2016 | StreetLight Data | Series B | 10M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
| 10/2012 | Mirna Therapeutics | Series C | 34.5M |
| 12/2013 | Infinio | Series B | 12M |
| 2/2019 | KenSci | Series B | 22M |
| 1/2021 | Coho Therapeutics | Seed Round | - |
| 4/2018 | SiFive | Series C | 50.6M |
| 5/2017 | Hyalex Orthopaedics | Series A | 16M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 10/2012 | Clinipace | Series C | 9M |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 10/2019 | IonQ | Series B | 55M |
| 8/2020 | Censys | Series A | 15.5M |
| 5/2016 | Aptinyx | Series A | 0 |
| 12/2015 | Everactive | Series B | 16.5M |
| 4/2018 | NuMat Technologies | Series B | 0 |
| 9/2021 | Corelight | Series D | 0 |
| 6/2022 | MicroTransponder | Series E | 0 |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 11/2012 | Cardioxyl Pharmaceuticals | Series B | 28M |
| 7/2021 | Glyphic Biotechnologies | Seed | 6M |
| 7/2019 | Menlo Security | Series D | 75M |
| 6/2022 | Nikola Labs | Series A | 0 |
| 11/2020 | Menlo Security | Series E | 100M |
| 11/2014 | Menlo Security | Series A | 10.5M |
| 7/2014 | Faraday Pharmaceuticals | Series A | - |
| 3/2015 | Kura Oncology | Private Equity Round | 60M |
| 9/2021 | Vanqua Bio | Series B | 85M |
| 3/2018 | Cyteir Therapeutics | Series B | 29M |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 1/2011 | Tangent Medical Technologies | Seed Round | 2.5M |
| 11/2015 | Body Labs | Series A | 0 |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 6/2018 | Ambiq Micro | Venture Round | 0 |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 8/2017 | Neuros Medical | Series A | 20M |
| 4/2020 | Atsena Therapeutics | Venture Round | 8.2M |
| 3/2022 | Brimstone Energy | Series A | 0 |
| 7/2018 | Seismos | Venture Round | 0 |
| 2/2017 | PMV Pharmaceuticals | Series B | 74M |
| 6/2012 | Tangent Medical Technologies | Venture Round | 7.9M |
| 5/2010 | Gevo | Series D | 0 |
| 1/2021 | Neuros Medical | Series B | 0 |
| 3/2015 | Paracosm | Venture Round | 812k |
| 2/2018 | CounterFlow | Seed Round | 0 |
| 8/2009 | Gevo | Venture Round | 0 |
| 5/2018 | Beam Therapeutics | Series A | 87M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 9/2020 | Nido Biosciences | Venture Round | 18.4M |
| 12/2017 | Aptinyx | Series B | 70M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 5/2019 | LunaDNA | Venture Round | 4.6M |
| 9/2015 | Faraday Pharmaceuticals | Series A | 30M |
| 3/2012 | Receptos | Venture Round | 30M |
| 12/2014 | PMV Pharmaceuticals | Series A | 30M |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 4/2015 | Clarifai | Series A | 10M |
| 4/2021 | Hack The Box | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Lastline | Series C | 0 |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 1/2014 | Menlo Security | Seed Round | - |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 10/2020 | Q32 Bio | Series B | 60M |
| 9/2013 | Otonomy | Series C | 45.9M |
| 1/2017 | Pionyr Immunotherapeutics | Series A | 8M |
| 6/2020 | StreetLight Data | Series D | 15M |
| 8/2019 | Cleave Therapeutics | Series C | 0 |
| 4/2013 | SkyTree, Inc. | Series A | 18M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 2/2018 | Picwell | Series B | 0 |
| 12/2016 | Merganser Biotech | Venture Round | - |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 10/2013 | Immune Design | Series C | 49M |
| 6/2017 | Vector Launch | Series A | 0 |
| 9/2011 | Clinipace | Series C | 15M |
| 11/2012 | Tangent Medical Technologies | Series B | 8.6M |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 12/2008 | Luxtera | Series D | 0 |
| 10/2022 | Normunity | Series A | 65M |
| 10/2017 | Everactive | Venture Round | 40.3M |
| 7/2015 | Voxel8 | Series A | 12M |
| 11/2011 | Sera Prognostics | Series A | 19.3M |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 2/2014 | Guardant Health | Series A | 10M |
| 2/2016 | Ribon Therapeutics | Series A | 24M |
| 12/2015 | Enlibrium | Series A | 15M |
| 12/2015 | Ribon Therapeutics | Venture Round | 10M |
| 6/2017 | Algorithmia | Series A | 10.5M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2021 | Verve Motion | Series A | 15M |
| 12/2017 | Menlo Security | Series C | 40.3M |
| 1/2019 | Seismos | Venture Round | 0 |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 6/2015 | Menlo Security | Series B | 25M |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 11/2014 | Paracosm | Seed Round | 3.3M |
| 10/2009 | Kolltan Pharmaceuticals | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 8/2013 | Evolv Technology | Series A | 11.8M |
| 6/2011 | SolarBridge Technologies | Series C | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 5/2012 | SolarBridge Technologies | Series D | 25M |
| 12/2020 | Atsena Therapeutics | Series A | 0 |
| 3/2019 | Hyalex Orthopaedics | Series A | 17M |
| 6/2019 | Artizan Biosciences | Series A | 0 |
| 3/2018 | Clinipace | Venture Round | 0 |
| 1/2023 | Opsys Tech | Series C | 0 |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 3/2013 | Receptos | Series B | 30M |
| 3/2021 | EGenesis | Series C | 0 |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 11/2017 | Quantum Circuits | Series A | 18M |
| 8/2016 | Ambiq Micro | Series D | 9.4M |
| 6/2013 | Kymeta | Series C | 50M |
| 9/2015 | Selecta Biosciences | Series E | 38M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 7/2010 | MC10 | Series A | 0 |
| 3/2021 | Artizan Biosciences | Series A | 0 |
| 5/2019 | LunaPBC | Venture Round | 4.6M |
| 12/2011 | Liquid Light | Series A | 5.5M |
| 3/2014 | Kolltan Pharmaceuticals | Series D | 60M |
| 11/2009 | Virdante Pharmaceuticals | Series A | 30M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 6/2018 | Embodied | Series A | 22M |
| 10/2018 | Modis Therapeutics | Series A | 30M |
| 7/2017 | Perceptive Automata | Seed Round | 0 |
| 2/2012 | SkyTree, Inc. | Seed Round | 1.5M |
| 5/2018 | Escient Pharmaceuticals | Series A | 40M |
| 7/2008 | Immune Design | Series A | 18M |
| 2/2002 | Luxtera | Series A | 6.8M |
| 6/2010 | Corridor Pharmaceuticals | Series A | 0 |
| 10/2009 | Corridor Pharmaceuticals | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 4/2014 | Otonomy | Series D | 49M |
| 6/2011 | MC10 | Series B | 0 |
| 4/2015 | Seismos | Series A | 4M |
| 6/2019 | SiFive | Series D | 65.4M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 5/2018 | Medisix Therapeutics | Series A | 20M |
| 9/2014 | Liquid Light | Series B | 15M |
| 7/2017 | Corelight | Series A | 9.2M |
| 7/2008 | Kolltan Pharmaceuticals | Series A | 0 |
| 11/2014 | Ambiq Micro | Series C | 15.6M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 7/2015 | Picwell | Series A | 4M |
| 12/2017 | Pionyr Immunotherapeutics | Series B | 0 |
| 8/2018 | MC10 | Venture Round | 0 |
| 7/2018 | StreetLight Data | Series C | 0 |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 6/2014 | Jibo | Seed Round | 5M |
| 8/2020 | SiFive | Series E | 0 |
| 11/2011 | Tangent Medical Technologies | Series A | 4.5M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 5/2017 | SiFive | Series B | 8.5M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 2/2017 | Arrakis Therapeutics | Series A | 38M |
| 7/2010 | Immune Design | Series B | 32M |
| 11/2014 | Everactive | Series A | 5.3M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 8/2014 | Algorithmia | Seed Round | 2.6M |
| 7/2017 | IonQ | Series A | 20M |
| 10/2019 | ArsenalBio | Series A | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 3/2018 | Dracen Pharmaceuticals | Series A | 40M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 6/2016 | Cell Design Labs | Equity | 34.4M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 10/2022 | Metalenz | Series B | 0 |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 1/2016 | Kymeta | Series D | 62M |
| 5/2019 | Algorithmia | Series B | 25M |
| 3/2011 | Aerie Pharmaceuticals | Series B | 41.4M |
| 5/2015 | Precision BioSciences | Series A | 0 |
| 8/2005 | Gevo | Series A | 500k |
| 9/2017 | Selecta Biosciences | Post-IPO Equity | 21M |
| 7/2018 | Infinite Uptime | Series A | 5M |
| 10/2018 | Vector Launch | Series B | 0 |
| 7/2018 | Spero Therapeutics | Post-IPO Equity | 75M |
| 9/2020 | Palladio Biosciences | Series B | 20M |
| 10/2019 | Cyteir Therapeutics | Series B | 40.2M |
| 1/2017 | KenSci | Series A | 8.5M |
| 12/2018 | Elementary Robotics | Seed Round | 0 |
| 12/2012 | MC10 | Series C | 10M |
| 2/2019 | Vor Biopharma | Series A | 42M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 3/2016 | Capella BioScience | Series A | 15.5M |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2022 | Nikola Labs | Series A | 0 |
| 6/2022 | MicroTransponder | Series E | 0 |
| 3/2022 | Brimstone Energy | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 9/2021 | Vanqua Bio | Series B | 0 |
| 9/2021 | Corelight | Series D | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
